We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simple Blood Test Assesses Colon Cancer Risk

By LabMedica International staff writers
Posted on 06 Nov 2012
A novel blood test will help enable the physician to monitor the patient's colorectal cancer (CRC) risk over the course of their screening lifetime, especially for those who are aged 50 years or more. More...


The blood test does not require any advance preparation, only the collection of a small blood sample, and differs from other tests that often require fasting and other dietary restrictions and with those patients having to collect multiple fecal samples over the course of three days or more.

The test, known as the COLOGIC test, is based on the discovery that approximately nine out of ten patients with colorectal cancer are deficient in novel anticancer and anti-inflammatory metabolites in their blood. COLOGIC detects this deficiency to determine patient risk. The COLOGIC test has a sensitivity of 86% versus an average range of 35% to 61% for fecal occult blood test/fecal immunochemical test (FOBT/FIT). The specificity of the test is reportedly 90%.

Clinical support for COLOGIC includes four published papers outlining the science and clinical outcomes of a study involving 4,923 patients. The test measures levels of gastrointestinal tract acid-446 (GTA-446), a long-chain polyunsaturated fatty acid present in the serum. The CRC incidence rate in subjects undergoing colonoscopy with low GTA-446 levels was over six times higher than for subjects with normal GTA-446 levels and twice that of subjects with gastrointestinal symptoms.

The COLOGIC test was developed by Phenomenome Discoveries Inc., (Saskatoon, SK, Canada) and will provide an easily understood result on whether the individual has an elevated risk for colon cancer. Mario Castelli MD, a gastroenterologist, said, “Colorectal cancer is a completely preventable disease if we screen for it, and it gets more common as we get older, so that's why the recommendation is, usually starting at the age of 50, that everyone should be screened. This is a much simpler test. The patient just goes to the laboratory without any preparation, have a blood sample drawn and the results go to your physician within days.” It should be noted that COLOGIC test is not a substitute to colonoscopy. A positive test result should be followed up with a colonoscopy to confirm the presence of cancer.

Related Links:

Phenomenome Discoveries Inc.



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.